Who Owns Monte Rosa Therapeutics Stock?
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 115.78%
- Institutions (% of float)
- 116.43%
- Held by insiders
- 0.56%
- Institutional holders
- 258
- Institutions 99.4%
- Insiders 0.6%
- Public and other 0.0%
Who owns Monte Rosa Therapeutics stock?
Institutional investors own about 115.8% of Monte Rosa Therapeutics's shares, spread across 258 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.56% of GLUE.
The largest institutional holders are Price (T.Rowe) Associates Inc (8.61%), Blackrock Inc. (8.42%) and Vestal Point Capital, LP (8.34%). Together, the top 10 institutions control 59.9% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their GLUE positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of GLUE
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Price (T.Rowe) Associates Inc | 7.36M | 8.61% | -17.0% |
| Blackrock Inc. | 7.19M | 8.42% | +5.1% |
| Vestal Point Capital, LP | 7.13M | 8.34% | +55.0% |
| NEA Management Company, LLC | 6.69M | 7.83% | -13.0% |
| Baker Bros. Advisors, LP | 4.35M | 5.09% | 0.0% |
| BVF Inc. | 4.28M | 5.00% | -4.1% |
| TCG Crossover Management, LLC | 3.78M | 4.43% | -18.2% |
| State Street Corporation | 3.72M | 4.36% | -0.3% |
| Vanguard Capital Management LLC | 3.48M | 4.07% | +1.9% |
| Versant Venture Management, LLC | 3.18M | 3.72% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of GLUE
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.55M | 2.99% |
| T. Rowe Price New Horizons Fund, Inc. | 2.23M | 2.61% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.11M | 2.46% |
| iShares Trust-iShares Russell 2000 ETF | 1.92M | 2.24% |
| T. Rowe Price Health Sciences Fund, Inc. | 1.82M | 2.13% |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 1.38M | 1.61% |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 983.09K | 1.15% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 810.82K | 0.95% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 785.01K | 0.92% |
| iShares Trust-iShares Russell 2000 Growth ETF | 694.65K | 0.81% |
Frequently asked questions
Who is the largest shareholder of Monte Rosa Therapeutics?
Price (T.Rowe) Associates Inc is the largest institutional shareholder of GLUE, owning 8.61% of shares outstanding (7.36M shares) as of its latest 13F filing.
What percentage of Monte Rosa Therapeutics is owned by institutions?
Institutions own about 115.8% of GLUE shares and 116.4% of the public float.
How much of Monte Rosa Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.56% of GLUE shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.